SFX by Ex Libris Inc.

Title:	Differentiating effects of the glucagon-like peptide-1 analogue exendin-4 in a human neuronal cell model
Source:	Cellular and Molecular Life Sciences [1420-682X] Luciani, Paola yr:2010

Basic

Full text

Full text available via SpringerLINK Contemporary 1997-Present

Year:

Volume:

Issue:

Start Page:

Document delivery

Request document via Library/Bibliothek

Users interested in this article also expressed an interest in the following:
description	1.	Kan, M. "Glucagon-Like Peptide 1, Insulin, Sensory Neurons, and Diabetic Neuropathy." Journal of neuropathology and experimental neurology 71.6 (2012): 494-510.
description	2.	Xu, A. "Exendin-4 Protects Mitochondria from Reactive Oxygen Species Induced Apoptosis in Pancreatic Beta Cells." PLoS ONE 8.10 (2013).
description	3.	Gallenberger, M. "Dynamics of glucose and insulin concentration connected to the ß-cell cycle: model development and analysis." Theoretical biology and medical modelling 9.1 (2012): 46-46.
description	4.	Rachmany, L. "Exendin-4 induced glucagon-like peptide-1 receptor activation reverses behavioral impairments of mild traumatic brain injury in mice." Age : Journal of the American Aging Association 35.5 (2012): 1-16.
description	5.	Fu, Z. "Protection of exenatide for retinal ganglion cells with different glucose concentrations." Peptides 37.1 (2012): 25-31.
description	6.	Zochodne, Douglas W. "Reversing neuropathic deficits." Journal of the peripheral nervous system 17.2 (2012): 4-9.
description	7.	Singh, B. "Resistance to trophic neurite outgrowth of sensory neurons exposed to insulin." Journal of neurochemistry 121.2 (2012): 263-276.
description	8.	Sivertsen, J. "The effect of glucagon-like peptide 1 on cardiovascular risk." Nature reviews. Cardiology 9.4 (2012): 209-222.
description	9.	Lim, D. "Improved MIN6 β-Cell Function on Self-Assembled Peptide Amphiphile Nanomatrix Inscribed with Extracellular Matrix-Derived Cell Adhesive Ligands." Macromolecular bioscience 13.10 (2013): 1404-1412.
description	10.	Jin, J. "Related expressional change of HIF-1Î± to the neuroprotective activity of exendin-4 in transient global ischemia." NeuroReport 25.1 (2014): 65-70.
description	11.	Cigliola, V. "Connexins and β-cell functions." Diabetes research and clinical practice 99.3 (2012): 250-259.
description	12.	Hölscher, C. "Potential Role of Glucagon-Like Peptide-1 (GLP-1) in Neuroprotection." CNS drugs 26.10 (2012): 871-882.
description	13.	Avdesh, A. "Pharmacological effects of cannabinoids on the reference and working memory functions in mice." Psychopharmacology 225.2 (2012): 483-494.
description	14.	Chowen, J.A. A. "Increased glucagon-like peptide-1 receptor expression in glia after mechanical lesion of the rat brain." Neuropeptides 33.3 (1999): 212-215.
description	15.	Perry, T. "The glucagon-like peptides: a double-edged therapeutic sword?" Trends in Pharmacological Sciences 24.7 (2003): 377-383.
description	16.	American Diabetes, D. "Diagnosis and classification of diabetes mellitus." Diabetes care 29.1 (2003): 37-8.
description	17.	Roden, M. "Diabetes mellitus - Definition, classification and diagnosis." Wiener klinische Wochenschrift 119.SPUUL. 2 (2007): 5-7.
description	18.	Alberti, K G M. "Definition, diagnosis and classification of diabetes mellitus and its complications part 1: Diagnosis and classification of diabetes mellitus - Provisional report of a WHO consultation." Diabetic medicine 15.7 (1998): 539-553.
description	19.	American Diabetes Association (ADbA). "Diagnosis and classification of diabetes mellitus (position statement)." Diabetes care 27.SUPPL. 1 (2004): 1-10.
description	20.	association. "Standards of Medical Care in Diabetes-2013." Diabetes care 36.1 (2013): 11-66.